Description
The multi drug-resistant cell line MES-SA/Dx5 was derived from the human uterine sarcoma cell line MES-SA which was originally obtained from a tumour from a 56-year-old Caucasian female at the time of hysterectomy. The Dx5 variant exhibits a 100-fold resistance to doxorubicin and has a reported doubling time of 30 hours. The two additional marker chromosomes indicate clonal selection during drug selection. MES-SA/Dx-5 cells exhibit marked cross-resistance to a number of chemotherapeutic agents (including daunorubicin, dactinomycin, vincristine, taxol, colchicine) and moderate cross-resistance to mitomycin C and melphalan. Cross resistance to bleomycin, cisplatin, carmustine, 5-fluorouracil or methotrexate was not observed.
Adherent Suspension
Adherent
Suggested Medium
McCoy's 5a + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Quality Control
MES-SA/Dx-5 Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Shippment
MES-SA/Dx-5 Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
MES-SA/Dx-5 Cell Line is for research use only
